BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laurent-puig P, Zucman-rossi J. Genetics of hepatocellular tumors. Oncogene 2006;25:3778-86. [DOI: 10.1038/sj.onc.1209547] [Cited by in Crossref: 243] [Cited by in F6Publishing: 220] [Article Influence: 16.2] [Reference Citation Analysis]
Number Citing Articles
1 Rebbani K, Marchio A, Ezzikouri S, Afifi R, Kandil M, Bahri O, Triki H, El Feydi AE, Dejean A, Benjelloun S, Pineau P. TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma. Mol Cancer 2015;14:74. [PMID: 25889455 DOI: 10.1186/s12943-015-0340-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
2 Zhang Y, Andrews GK, Wang L. Zinc-induced Dnmt1 expression involves antagonism between MTF-1 and nuclear receptor SHP. Nucleic Acids Res 2012;40:4850-60. [PMID: 22362755 DOI: 10.1093/nar/gks159] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
3 Huang P, Xu Q, Yan Y, Lu Y, Hu Z, Ou B, Zhang H, Mao K, Zhang J, Wang J, Xiao Z. HBx/ERα complex-mediated LINC01352 downregulation promotes HBV-related hepatocellular carcinoma via the miR-135b-APC axis. Oncogene 2020;39:3774-89. [PMID: 32157216 DOI: 10.1038/s41388-020-1254-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
4 Méniel V, Megges M, Young MA, Cole A, Sansom OJ, Clarke AR. Apc and p53 interaction in DNA damage and genomic instability in hepatocytes. Oncogene 2015;34:4118-29. [PMID: 25347740 DOI: 10.1038/onc.2014.342] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
5 Castello G, Scala S, Palmieri G, Curley SA, Izzo F. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol. 2010;134:237-250. [PMID: 19910258 DOI: 10.1016/j.clim.2009.10.007] [Cited by in Crossref: 100] [Cited by in F6Publishing: 90] [Article Influence: 8.3] [Reference Citation Analysis]
6 Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev. 2010;36:43-53. [PMID: 19910122 DOI: 10.1016/j.ctrv.2009.10.002] [Cited by in Crossref: 120] [Cited by in F6Publishing: 97] [Article Influence: 10.0] [Reference Citation Analysis]
7 Le Naour F, Sandt C, Peng C, Trcera N, Chiappini F, Flank AM, Guettier C, Dumas P. In situ chemical composition analysis of cirrhosis by combining synchrotron fourier transform infrared and synchrotron X-ray fluorescence microspectroscopies on the same tissue section. Anal Chem 2012;84:10260-6. [PMID: 23121424 DOI: 10.1021/ac302072t] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
8 Ikeda A, Shimizu T, Matsumoto Y, Fujii Y, Eso Y, Inuzuka T, Mizuguchi A, Shimizu K, Hatano E, Uemoto S, Chiba T, Marusawa H. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma. Gastroenterology 2014;146:222-32.e35. [PMID: 24055508 DOI: 10.1053/j.gastro.2013.09.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
9 Ghosh R, Topinka J, Joad JP, Dostal M, Sram RJ, Hertz-Picciotto I. Air pollutants, genes and early childhood acute bronchitis. Mutat Res 2013;749:80-6. [PMID: 23648357 DOI: 10.1016/j.mrfmmm.2013.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
10 Waisberg J, Saba GT. Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma. World J Hepatol 2015;7:2631-5. [PMID: 26609340 DOI: 10.4254/wjh.v7.i26.2631] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
11 Ruptier C, De Gaspéris A, Ansieau S, Granjon A, Tanière P, Lafosse I, Shi H, Petitjean A, Taranchon-Clermont E, Tribollet V. TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expression. Oncogene. 2011;30:4656-4665. [PMID: 21643019 DOI: 10.1038/onc.2011.171] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
12 Huang W, Mehta D, Sif S, Kent LN, Jacob ST, Ghoshal K, Mehta KD. Dietary fat/cholesterol-sensitive PKCβ-RB signaling: Potential role in NASH/HCC axis. Oncotarget 2017;8:73757-65. [PMID: 29088742 DOI: 10.18632/oncotarget.17890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Graña X, Knudsen ES. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology 2010;138:1920-30. [PMID: 20100483 DOI: 10.1053/j.gastro.2010.01.007] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 7.4] [Reference Citation Analysis]
14 Gnatenko DV, Xu X, Zhu W, Schmidt VA. Transcript profiling identifies iqgap2(-/-) mouse as a model for advanced human hepatocellular carcinoma. PLoS One 2013;8:e71826. [PMID: 23951254 DOI: 10.1371/journal.pone.0071826] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
15 Jeng JE, Tsai HR, Chuang LY, Tsai JF, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML. Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma. Medicine (Baltimore). 2009;88:349-357. [PMID: 19910749 DOI: 10.1097/md.0b013e3181c10477] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
16 Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, Wculek SK, Hammer M, Zenz R, Peck-Radosavljevic M. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol. 2014;16:972-977. [PMID: 25173978 DOI: 10.1038/ncb3031] [Cited by in Crossref: 136] [Cited by in F6Publishing: 126] [Article Influence: 19.4] [Reference Citation Analysis]
17 Pérez V. Viral hepatitis: historical perspectives from the 20th to the 21st century. Arch Med Res. 2007;38:593-605. [PMID: 17613350 DOI: 10.1016/j.arcmed.2006.09.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Liu YX, Zhang SF, Ji YH, Guo SJ, Wang GF, Zhang GW. Whole-exome sequencing identifies mutated PCK2 and HUWE1 associated with carcinoma cell proliferation in a hepatocellular carcinoma patient. Oncol Lett 2012;4:847-51. [PMID: 23205112 DOI: 10.3892/ol.2012.825] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
19 van Hengel J, D’hooge P, Hooghe B, Wu X, Libbrecht L, De Vos R, Quondamatteo F, Klempt M, Brakebusch C, van Roy F. Continuous Cell Injury Promotes Hepatic Tumorigenesis in Cdc42-Deficient Mouse Liver. Gastroenterology 2008;134:781-92. [DOI: 10.1053/j.gastro.2008.01.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
20 Yang B, Du Z, Gao YT, Lou C, Zhang SG, Bai T, Wang YJ, Song WQ. Methylation of Dickkopf-3 as a prognostic factor in cirrhosis-related hepatocellular carcinoma. World J Gastroenterol. 2010;16:755-763. [PMID: 20135726 DOI: 10.3748/wjg.v16.i6.755] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
21 Kudo M. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. Dig Dis. 2011;29:273-277. [PMID: 21829017 DOI: 10.1159/000327558] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
22 Feng GJ, Cotta W, Wei XQ, Poetz O, Evans R, Jardé T, Reed K, Meniel V, Williams GT, Clarke AR. Conditional disruption of Axin1 leads to development of liver tumors in mice. Gastroenterology. 2012;143:1650-1659. [PMID: 22960659 DOI: 10.1053/j.gastro.2012.08.047] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
23 Mayhew CN, Carter SL, Fox SR, Sexton CR, Reed CA, Srinivasan SV, Liu X, Wikenheiser-Brokamp K, Boivin GP, Lee JS. RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology. 2007;133:976-984. [PMID: 17854601 DOI: 10.1053/j.gastro.2007.06.025] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
24 Sherwood V. WNT signaling: an emerging mediator of cancer cell metabolism? Mol Cell Biol. 2015;35:2-10. [PMID: 25348713 DOI: 10.1128/mcb.00992-14] [Cited by in Crossref: 93] [Cited by in F6Publishing: 62] [Article Influence: 13.3] [Reference Citation Analysis]
25 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1] [Reference Citation Analysis]
26 Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links . Ann N Y Acad Sci. 2009;1155:206-221. [PMID: 19250206 DOI: 10.1111/j.1749-6632.2009.03704.x] [Cited by in Crossref: 266] [Cited by in F6Publishing: 238] [Article Influence: 22.2] [Reference Citation Analysis]
27 He AR, Soe K, El Zouhairi M. Current problems with systemic treatment of advanced hepatocellular cancer. Curr Probl Cancer 2010;34:131-49. [PMID: 20417353 DOI: 10.1016/j.currproblcancer.2010.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
28 Kijima H, Sawada T, Tomosugi N, Kubota K. Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer. 2008;8:167. [PMID: 18541040 DOI: 10.1186/1471-2407-8-167] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
29 Senni N, Savall M, Cabrerizo Granados D, Alves-guerra M, Sartor C, Lagoutte I, Gougelet A, Terris B, Gilgenkrantz H, Perret C, Colnot S, Bossard P. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut 2019;68:322-34. [DOI: 10.1136/gutjnl-2017-315448] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 13.7] [Reference Citation Analysis]
30 Pineau P, Marchio A, Battiston C, Cordina E, Russo A, Terris B, Qin LX, Turlin B, Tang ZY, Mazzaferro V. Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res. 2008;653:6-13. [PMID: 18467159 DOI: 10.1016/j.mrgentox.2008.01.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
31 Caillot F, Derambure C, Bioulac-Sage P, Francois A, Scotte M, Goria O, Hiron M, Daveau M, Salier JP. Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J Gastroenterol 2009;15:300-9. [PMID: 19140229 DOI: 10.3748/wjg.15.300] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
32 Jeng J, Tsai J, Chuang L, Ho M, Lin Z, Hsieh M, Chen S, Chuang W, Wang L, Yu M, Dai C, Chang J. Heat Shock Protein A1B 1267 Polymorphism Is Highly Associated With Risk and Prognosis of Hepatocellular Carcinoma: A Case-Control Study. Medicine 2008;87:87-98. [DOI: 10.1097/md.0b013e31816be95c] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
33 Götzel K, Chemnitzer O, Maurer L, Dietrich A, Eichfeld U, Lyros O, Moulla Y, Niebisch S, Mehdorn M, Jansen-Winkeln B, Vieth M, Hoffmeister A, Gockel I, Thieme R. In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett's sequence. BMC Gastroenterol 2019;19:38. [PMID: 30841855 DOI: 10.1186/s12876-019-0957-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Wang W, Xu L, Liu P, Jairam K, Yin Y, Chen K, Sprengers D, Peppelenbosch MP, Pan Q, Smits R. Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of β-Catenin Signaling. Neoplasia 2016;18:711-23. [PMID: 27851986 DOI: 10.1016/j.neo.2016.10.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
35 Bioulac-sage P, Balabaud C, Zucman-rossi J. Les tumeurs hépatocytaires bénignes – des connaissances récentes : de la biologie moléculaire au diagnostic. Gastroentérologie Clinique et Biologique 2008;32:296-303. [DOI: 10.1016/j.gcb.2008.02.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
36 Liu J, Ni W, Xiao M, Jiang F, Ni R. Decreased expression and prognostic role of mitogen-activated protein kinase phosphatase 4 in hepatocellular carcinoma. J Gastrointest Surg 2013;17:756-65. [PMID: 23325341 DOI: 10.1007/s11605-013-2138-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
37 Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Anders RA, Gao ZH. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis. Histopathology 2010;56:683-93. [PMID: 20546333 DOI: 10.1111/j.1365-2559.2010.03554.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
38 Kumada T, Toyoda H, Yasuda S, Miyake N, Ito T, Tanaka J. Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis. J Viral Hepat 2021;28:508-16. [PMID: 33306854 DOI: 10.1111/jvh.13457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Herr I, Groth A, Schemmer P, Büchler MW. Adult stem cells in progression and therapy of hepatocellular carcinoma. Int J Cancer 2007;121:1875-82. [DOI: 10.1002/ijc.23041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
40 Niller HH, Banati F, Ay E, Minarovits J. Epigenetic Changes in Virus-Associated Neoplasms. In: Minarovits J, Niller HH, editors. Patho-Epigenetics of Disease. New York: Springer; 2012. pp. 179-225. [DOI: 10.1007/978-1-4614-3345-3_8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
41 Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008;47:1955-1963. [PMID: 18433021 DOI: 10.1002/hep.22256] [Cited by in Crossref: 497] [Cited by in F6Publishing: 457] [Article Influence: 38.2] [Reference Citation Analysis]
42 Zucman-Rossi J, Laurent-Puig P. Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics. 2007;8:997-1003. [PMID: 17716233 DOI: 10.2217/14622416.8.8.997] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
43 Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, Yu E, Merle P, Wands JR. Functional interaction between Wnt3 and Frizzled-7 Leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol. 2008;48:780-791. [PMID: 18313787 DOI: 10.1016/j.jhep.2007.12.020] [Cited by in Crossref: 124] [Cited by in F6Publishing: 118] [Article Influence: 9.5] [Reference Citation Analysis]
44 Lu JW, Ho YJ, Yang YJ, Liao HA, Ciou SC, Lin LI, Ou DL. Zebrafish as a disease model for studying human hepatocellular carcinoma. World J Gastroenterol 2015;21:12042-58. [PMID: 26576090 DOI: 10.3748/wjg.v21.i42.12042] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
45 Niu ZS, Niu XJ, Wang WH. Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol 2016;22:9069-95. [PMID: 27895396 DOI: 10.3748/wjg.v22.i41.9069] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 69] [Article Influence: 18.5] [Reference Citation Analysis]
46 Wands JR, Kim M. WNT/β-catenin signaling and hepatocellular carcinoma. Hepatology 2014;60:452-4. [PMID: 24644061 DOI: 10.1002/hep.27081] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
47 Hui KM. Human hepatocellular carcinoma: expression profiles-based molecular interpretations and clinical applications. Cancer Lett 2009;286:96-102. [PMID: 19095350 DOI: 10.1016/j.canlet.2008.11.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
48 Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T, Nakagawa H. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012;44:760-764. [PMID: 22634756 DOI: 10.1038/ng.2291] [Cited by in Crossref: 561] [Cited by in F6Publishing: 551] [Article Influence: 62.3] [Reference Citation Analysis]
49 He N, Park K, Zhang Y, Huang J, Lu S, Wang L. Epigenetic Inhibition of Nuclear Receptor Small Heterodimer Partner Is Associated With and Regulates Hepatocellular Carcinoma Growth. Gastroenterology 2008;134:793-802. [DOI: 10.1053/j.gastro.2008.01.006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 5.5] [Reference Citation Analysis]
50 Williams G. Chemicals with Carcinogenic Activity in Rodent Liver. Comprehensive Toxicology. Elsevier; 2010. pp. 221-50. [DOI: 10.1016/b978-0-08-046884-6.01009-5] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
51 Huan L, Liang LH, He XH. Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med 2016;13:407-25. [PMID: 28154773 DOI: 10.20892/j.issn.2095-3941.2016.0071] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
52 Takagi K, Takayama T, Midorikawa Y, Hasegawa H, Ochiai T, Moriguchi M, Higaki T, Soma M, Nagase H, Fujiwara K. Cell division cycle 34 is highly expressed in hepatitis C virus-positive hepatocellular carcinoma with favorable phenotypes. Biomed Rep 2017;7:41-6. [PMID: 28685058 DOI: 10.3892/br.2017.912] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
53 Badawy AA, El-Rabat A, Elshazly TA, Ali SA, Alruwaili AM, Gad DF, Dawoud MG, Elmasry EE, Zaki ME. Association of 32-bp deletion polymorphism and promoter methylation of PTEN and hepatitis C virus induced hepatocellular carcinoma. Br J Biomed Sci 2019;76:195-7. [PMID: 31109254 DOI: 10.1080/09674845.2019.1620475] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Wu BH, Chen H, Cai CM, Fang JZ, Wu CC, Huang LY, Wang L, Han ZG. Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription of CDKN1A 686. Oncotarget 2016;7:6847-63. [PMID: 26760772 DOI: 10.18632/oncotarget.6867] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
55 Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008;8:714-24. [PMID: 19143056 DOI: 10.1038/nrc2401] [Cited by in Crossref: 238] [Cited by in F6Publishing: 221] [Article Influence: 19.8] [Reference Citation Analysis]
56 Berasain C, Castillo J, Perugorría M, Prieto J, Avila M. Amphiregulin: A new growth factor in hepatocarcinogenesis. Cancer Letters 2007;254:30-41. [DOI: 10.1016/j.canlet.2007.01.015] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
57 Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, François C, Chatelain D, Debuysscher V, Barbare JC, Chauffert B, Galmiche A. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett 2015;356:971-7. [PMID: 25444922 DOI: 10.1016/j.canlet.2014.11.014] [Cited by in Crossref: 116] [Cited by in F6Publishing: 108] [Article Influence: 16.6] [Reference Citation Analysis]
58 Wu J, Xue R, Jiang R, Meng Q. Characterization of metabolic landscape in hepatocellular carcinoma. WJGO 2021;13:1144-56. [DOI: 10.4251/wjgo.v13.i9.1144] [Reference Citation Analysis]
59 Kudo M. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis. 2011;29:289-302. [PMID: 21829020 DOI: 10.1159/000327562] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
60 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 103] [Article Influence: 21.2] [Reference Citation Analysis]
61 Wang Z, Sheng YY, Gao XM, Wang CQ, Wang XY, Lu XU, Wei JW, Zhang KL, Dong QZ, Qin LX. β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Mol Clin Oncol 2015;3:936-40. [PMID: 26171210 DOI: 10.3892/mco.2015.569] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
62 Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979-992. [PMID: 17291746 DOI: 10.1016/j.ejca.2007.01.004] [Cited by in Crossref: 171] [Cited by in F6Publishing: 153] [Article Influence: 12.2] [Reference Citation Analysis]
63 Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol. 2008;48:163-170. [PMID: 17997499 DOI: 10.1016/j.jhep.2007.10.003] [Cited by in Crossref: 166] [Cited by in F6Publishing: 112] [Article Influence: 11.9] [Reference Citation Analysis]
64 Bharadwaj M, Roy G, Dutta K, Misbah M, Husain M, Hussain S. Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. Cancer Metastasis Rev. 2013;32:229-268. [PMID: 23114844 DOI: 10.1007/s10555-012-9412-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
65 Laumonier H, Bioulac-Sage P, Laurent C, Zucman-Rossi J, Balabaud C, Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology. 2008;48:808-818. [PMID: 18688875 DOI: 10.1002/hep.22417] [Cited by in Crossref: 223] [Cited by in F6Publishing: 164] [Article Influence: 17.2] [Reference Citation Analysis]
66 Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci. 2014;59:1688-1697. [PMID: 24573715 DOI: 10.1007/s10620-014-3058-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
67 Chen PJ. Genetic mutation in hepatic adenoma: seeing is believing. J Hepatol 2006;45:767-9. [PMID: 17034896 DOI: 10.1016/j.jhep.2006.09.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
68 Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442-450. [PMID: 22504333 DOI: 10.1016/j.jhep.2012.02.033] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 13.2] [Reference Citation Analysis]
69 Daud M, Rana MA, Husnain T, Ijaz B. Modulation of Wnt signaling pathway by hepatitis B virus. Arch Virol. 2017;162:2937-2947. [PMID: 28685286 DOI: 10.1007/s00705-017-3462-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
70 Chettiar ST, Malek R, Annadanam A, Nugent KM, Kato Y, Wang H, Cades JA, Taparra K, Belcaid Z, Ballew M, Manmiller S, Proia D, Lim M, Anders RA, Herman JM, Tran PT. Ganetespib radiosensitization for liver cancer therapy. Cancer Biol Ther 2016;17:457-66. [PMID: 26980196 DOI: 10.1080/15384047.2016.1156258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
71 Vinciguerra M, Foti M. PTEN at the crossroad of metabolic diseases and cancer in the liver. Annals of Hepatology 2008;7:192-9. [DOI: 10.1016/s1665-2681(19)31848-4] [Cited by in Crossref: 38] [Article Influence: 2.9] [Reference Citation Analysis]
72 Chang Q, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, Castranova V, Shi X, Chen F. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol 2009;50:323-33. [PMID: 19041150 DOI: 10.1016/j.jhep.2008.07.037] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 7.2] [Reference Citation Analysis]
73 Tang X, Wang Y, Fan Z, Ji G, Wang M, Lin J, Huang S, Meltzer SJ. Klotho: a tumor suppressor and modulator of the Wnt/β-catenin pathway in human hepatocellular carcinoma. Lab Invest 2016;96:197-205. [PMID: 26237271 DOI: 10.1038/labinvest.2015.86] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
74 Wang LJ, Bai L, Su D, Zhang T, Mao ZY. Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways. Mol Cell Biochem 2013;381:173-81. [PMID: 23749165 DOI: 10.1007/s11010-013-1700-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
75 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
76 Dong B, Lee JS, Park YY, Yang F, Xu G, Huang W, Finegold MJ, Moore DD. Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis. Nat Commun 2015;6:5944. [PMID: 25661872 DOI: 10.1038/ncomms6944] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 9.5] [Reference Citation Analysis]
77 Chun YS, Chaudhari P, Jang YY. Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int J Biol Sci. 2010;6:796-805. [PMID: 21179587 DOI: 10.7150/ijbs.6.796] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 5.7] [Reference Citation Analysis]
78 Fezza M, Moussa M, Aoun R, Haber R, Hilal G. DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: Implication of TGF-β1. PLoS One 2019;14:e0223252. [PMID: 31568519 DOI: 10.1371/journal.pone.0223252] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
79 Rousseau B, Ménard L, Haurie V, Taras D, Blanc J, Moreau-gaudry F, Metzler P, Hugues M, Boyault S, Lemière S, Canron X, Costet P, Cole M, Balabaud C, Bioulac-sage P, Zucman-rossi J, Rosenbaum J. Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology 2007;46:1108-18. [DOI: 10.1002/hep.21770] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 6.2] [Reference Citation Analysis]
80 Hale G, Liu X, Hu J, Xu Z, Che L, Solomon D, Tsokos C, Shafizadeh N, Chen X, Gill R, Kakar S. Correlation of exon 3 β-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma. Mod Pathol 2016;29:1370-80. [PMID: 27469330 DOI: 10.1038/modpathol.2016.122] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
81 Kim YD, Park CH, Kim HS, Choi SK, Rew JS, Kim DY, Koh YS, Jeung KW, Lee KH, Lee JS. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:110-118. [PMID: 18171349 DOI: 10.1111/j.1440-1746.2007.05250.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
82 Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 2007;26:2226-42. [PMID: 17401432 DOI: 10.1038/sj.onc.1210291] [Cited by in Crossref: 279] [Cited by in F6Publishing: 249] [Article Influence: 19.9] [Reference Citation Analysis]
83 Derambure C, Coulouarn C, Caillot F, Daveau R, Hiron M, Scotte M, Francois A, Duclos C, Goria O, Gueudin M, Cavard C, Terris B, Daveau M, Salier JP. Genome-wide differences in hepatitis C- vs alcoholism-associated hepatocellular carcinoma. World J Gastroenterol 2008;14:1749-58. [PMID: 18350606 DOI: 10.3748/wjg.14.1749] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
84 Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goñi S, Santamaría M, Prieto J, Avila MA. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) 2009;234:713-25. [PMID: 19429859 DOI: 10.3181/0901-MR-12] [Cited by in Crossref: 88] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
85 Zhou Y, Shi WY, He W, Yan ZW, Liu MH, Chen J, Yang YS, Wang YQ, Chen GQ, Huang Y. FAM122A supports the growth of hepatocellular carcinoma cells and its deletion enhances Doxorubicin-induced cytotoxicity. Exp Cell Res 2020;387:111714. [PMID: 31711919 DOI: 10.1016/j.yexcr.2019.111714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
86 Surana R, Sikka S, Cai W, Shin EM, Warrier SR, Tan HJ, Arfuso F, Fox SA, Dharmarajan AM, Kumar AP. Secreted frizzled related proteins: Implications in cancers. Biochim Biophys Acta 2014;1845:53-65. [PMID: 24316024 DOI: 10.1016/j.bbcan.2013.11.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 54] [Article Influence: 3.0] [Reference Citation Analysis]
87 Zekri AR, Youssef AS, Bakr YM, Gabr RM, Ahmed OS, Elberry MH, Mayla AM, Abouelhoda M, Bahnassy AA. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model. World J Gastroenterol 2016;22:4168-82. [PMID: 27122667 DOI: 10.3748/wjg.v22.i16.4168] [Reference Citation Analysis]
88 Takagi H, Sasaki S, Suzuki H, Toyota M, Maruyama R, Nojima M, Yamamoto H, Omata M, Tokino T, Imai K. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol. 2008;43:378-389. [PMID: 18592156 DOI: 10.1007/s00535-008-2170-0] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 6.2] [Reference Citation Analysis]
89 Sheng J, Kohno S, Okada N, Okahashi N, Teranishi K, Matsuda F, Shimizu H, Linn P, Nagatani N, Yamamura M, Harada K, Horike SI, Inoue H, Yano S, Kumar S, Kitajima S, Ajioka I, Takahashi C. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy. Hepatology 2021. [PMID: 33931882 DOI: 10.1002/hep.31872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
90 Chung W, Kim M, de la Monte S, Longato L, Carlson R, Slagle BL, Dong X, Wands JR. Activation of signal transduction pathways during hepatic oncogenesis. Cancer Lett. 2016;370:1-9. [PMID: 26433160 DOI: 10.1016/j.canlet.2015.09.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
91 Haker B, Fuchs S, Dierlamm J, Brümmendorf TH, Wege H. Absence of oncogenic transformation despite acquisition of cytogenetic aberrations in long-term cultured telomerase-immortalized human fetal hepatocytes. Cancer Letters 2007;256:120-7. [DOI: 10.1016/j.canlet.2007.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
92 Dong LW, Yang GZ, Pan YF, Chen Y, Tan YX, Dai RY, Ren YB, Fu J, Wang HY. The oncoprotein p28GANK establishes a positive feedback loop in β-catenin signaling. Cell Res 2011;21:1248-61. [PMID: 21691299 DOI: 10.1038/cr.2011.103] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
93 Cavard C, Colnot S, Audard V, Benhamouche S, Finzi L, Torre C, Grimber G, Godard C, Terris B, Perret C. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol. 2008;4:647-660. [PMID: 18922122 DOI: 10.2217/14796694.4.5.647] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
94 Wu MH, Ma WL, Hsu CL, Chen YL, Ou JH, Ryan CK, Hung YC, Yeh S, Chang C. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med 2010;2:32ra35. [PMID: 20484730 DOI: 10.1126/scitranslmed.3001143] [Cited by in Crossref: 99] [Cited by in F6Publishing: 117] [Article Influence: 9.0] [Reference Citation Analysis]
95 García-jiménez C. Wnt and Incretin Connections. Incretins and Insulin Secretion. Elsevier; 2010. pp. 355-87. [DOI: 10.1016/b978-0-12-381517-0.00014-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
96 Takahashi A, Tokita H, Takahashi K, Takeoka T, Murayama K, Tomotsune D, Ohira M, Iwamatsu A, Ohara K, Yazaki K, Koda T, Nakagawara A, Tani K. A novel potent tumour promoter aberrantly overexpressed in most human cancers. Sci Rep 2011;1:15. [PMID: 22355534 DOI: 10.1038/srep00015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
97 De Minicis S, Marzioni M, Benedetti A, Svegliati-Baroni G. New insights in hepatocellular carcinoma: from bench to bedside. Ann Transl Med 2013;1:15. [PMID: 25332959 DOI: 10.3978/j.issn.2305-5839.2013.01.06] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
98 Reed CA, Mayhew CN, McClendon AK, Knudsen ES. Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control. J Biol Chem 2010;285:1089-96. [PMID: 19887370 DOI: 10.1074/jbc.M109.043380] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
99 Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11-26. [PMID: 23258168 DOI: 10.1038/nrc3419] [Cited by in Crossref: 1221] [Cited by in F6Publishing: 1143] [Article Influence: 152.6] [Reference Citation Analysis]
100 Park SH, Lee SM, Kim YJ, Kim S. ChARM: Discovery of combinatorial chromatin modification patterns in hepatitis B virus X-transformed mouse liver cancer using association rule mining. BMC Bioinformatics 2016;17:452. [PMID: 28105934 DOI: 10.1186/s12859-016-1307-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
101 Guan YS, La Z, Yang L, He Q, Li P. p53 gene in treatment of hepatic carcinoma: status quo. World J Gastroenterol. 2007;13:985-992. [PMID: 17373730 DOI: 10.3748/wjg.v13.i7.985] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
102 Hirabayashi S, Baranski TJ, Cagan RL. Transformed Drosophila cells evade diet-mediated insulin resistance through wingless signaling. Cell 2013;154:664-75. [PMID: 23911328 DOI: 10.1016/j.cell.2013.06.030] [Cited by in Crossref: 85] [Cited by in F6Publishing: 68] [Article Influence: 10.6] [Reference Citation Analysis]
103 Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-sage P, Laurent-puig P, Zucman-rossi J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52. [DOI: 10.1002/hep.21467] [Cited by in Crossref: 693] [Cited by in F6Publishing: 622] [Article Influence: 49.5] [Reference Citation Analysis]
104 Matsuzaki K, Seki T, Okazaki K. TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases. J Gastroenterol 2014;49:971-81. [PMID: 24263677 DOI: 10.1007/s00535-013-0910-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
105 Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther. 2014;14:1205-1218. [PMID: 25199765 DOI: 10.1586/14737140.2014.949246] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
106 Wang T, Yao W, Shao Y, Zheng R, Huang F. PCAF fine-tunes hepatic metabolic syndrome, inflammatory disease, and cancer. J Cell Mol Med 2018;22:5787-800. [PMID: 30216660 DOI: 10.1111/jcmm.13877] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
107 Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, Vogel H, Sylvester KG, Thorgeirsson SS, Grompe M, Sage J. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med. 2011;208:1963-1976. [PMID: 21875955 DOI: 10.1084/jem.20110198] [Cited by in Crossref: 137] [Cited by in F6Publishing: 121] [Article Influence: 13.7] [Reference Citation Analysis]
108 Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009;49:821-31. [PMID: 19101982 DOI: 10.1002/hep.22695] [Cited by in Crossref: 109] [Cited by in F6Publishing: 95] [Article Influence: 9.1] [Reference Citation Analysis]
109 Luo X, Liu Y, Ma S, Liu L, Xie R, Wang S. WDR34 Activates Wnt/Beta-Catenin Signaling in Hepatocellular Carcinoma. Dig Dis Sci 2019;64:2591-9. [DOI: 10.1007/s10620-019-05583-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
110 Hollósi P, Váncza L, Karászi K, Dobos K, Péterfia B, Tátrai E, Tátrai P, Szarvas T, Paku S, Szilák L, Kovalszky I. Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1. Biomolecules 2020;10:E1356. [PMID: 32977498 DOI: 10.3390/biom10101356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
111 Strocchi E, Fornari F, Minguzzi M, Gramantieri L, Milazzo M, Rebuttini V, Breviglieri S, Camaggi CM, Locatelli E, Bolondi L, Comes-franchini M. Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. European Journal of Medicinal Chemistry 2012;48:391-401. [DOI: 10.1016/j.ejmech.2011.12.031] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
112 Lambert MP, Paliwal A, Vaissière T, Chemin I, Zoulim F, Tommasino M, Hainaut P, Sylla B, Scoazec JY, Tost J. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol. 2011;54:705-715. [PMID: 21146512 DOI: 10.1016/j.jhep.2010.07.027] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 9.1] [Reference Citation Analysis]
113 Jiang JH, Liu YF, Ke AW, Gu FM, Yu Y, Dai Z, Gao Q, Shi GM, Liao BY, Xie YH, Fan J, Huang XW, Zhou J. Clinical significance of the ubiquitin ligase UBE3C in hepatocellular carcinoma revealed by exome sequencing. Hepatology 2014;59:2216-27. [PMID: 24425307 DOI: 10.1002/hep.27012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
114 Khalid A, Hussain T, Manzoor S, Saalim M, Khaliq S. PTEN: A potential prognostic marker in virus-induced hepatocellular carcinoma. Tumour Biol 2017;39:101042831770575. [DOI: 10.1177/1010428317705754] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
115 Frenette C, Gish RG. Hepatocellular carcinoma: molecular and genomic guideline for the clinician. Clin Liver Dis 2011;15:307-21, vii-x. [PMID: 21689615 DOI: 10.1016/j.cld.2011.03.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
116 Frost K, Seir K, Lackner A, Grusch M, Grasl-Kraupp B, Schulte-Hermann R, Rodgarkia-Dara C. Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma? Br J Cancer 2011;104:1303-12. [PMID: 21407220 DOI: 10.1038/bjc.2011.53] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
117 Matouk IJ, Abbasi I, Hochberg A, Galun E, Dweik H, Akkawi M. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur J Gastroenterol Hepatol. 2009;21:688-692. [PMID: 19445043 DOI: 10.1097/meg.0b013e328306a3a2] [Cited by in Crossref: 139] [Cited by in F6Publishing: 91] [Article Influence: 12.6] [Reference Citation Analysis]
118 Wei BR, Edwards JB, Hoover SB, Tillman HS, Reed LT, Sills RC, Simpson RM. Altered {beta}-catenin accumulation in hepatocellular carcinomas of diethylnitrosamine-exposed rhesus macaques. Toxicol Pathol 2008;36:972-80. [PMID: 18978308 DOI: 10.1177/0192623308327120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
119 Shen J, Hu J, Wu J, Luo X, Li Y, Li J. Molecular characterization of long-term survivors of hepatocellular carcinoma. Aging (Albany NY) 2021;13:7517-37. [PMID: 33686022 DOI: 10.18632/aging.202615] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, Cunha AS, Bioulac-Sage P, Perret C. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene. 2007;26:774-780. [PMID: 16964294 DOI: 10.1038/sj.onc.1209824] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 10.7] [Reference Citation Analysis]
121 Saddic LA, Wirt S, Vogel H, Felsher DW, Sage J. Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. PLoS One 2011;6:e19758. [PMID: 21573126 DOI: 10.1371/journal.pone.0019758] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
122 Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51. [PMID: 20175032 DOI: 10.1055/s-0030-1247131] [Cited by in Crossref: 212] [Cited by in F6Publishing: 205] [Article Influence: 19.3] [Reference Citation Analysis]
123 Reed C, Hutcheson J, Mayhew CN, Witkiewicz AK, Knudsen ES. RB tumor suppressive function in response to xenobiotic hepatocarcinogens. Am J Pathol 2014;184:1853-9. [PMID: 24726645 DOI: 10.1016/j.ajpath.2014.02.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
124 Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis. 2008;1299-1305. [PMID: 18515282 DOI: 10.1093/carcin/bgn113] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 8.1] [Reference Citation Analysis]
125 Cha SW, Sohn JH, Kim SH, Kim YT, Kang SH, Cho MY, Kim MY, Baik SK. Interaction between the tumor microenvironment and resection margin in different gross types of hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:648-53. [PMID: 31483517 DOI: 10.1111/jgh.14848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Quetglas IM, Moeini A, Pinyol R, Llovet JM. Integration of genomic information in the clinical management of HCC. Best Pract Res Clin Gastroenterol 2014;28:831-42. [PMID: 25260311 DOI: 10.1016/j.bpg.2014.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
127 Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol. 2012;18:6005-6017. [PMID: 23155330 DOI: 10.3748/wjg.v18.i42.6005] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
128 Heindryckx F, Colle I, Van Vlierberghe H. Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol. 2009;90:367-386. [PMID: 19659896 DOI: 10.1111/j.1365-2613.2009.00656.x] [Cited by in Crossref: 232] [Cited by in F6Publishing: 205] [Article Influence: 19.3] [Reference Citation Analysis]
129 Duffy A, Greten T. Developing better treatments in hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;4:551-60. [DOI: 10.1586/egh.10.58] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
130 Krelin Y, Zhang L, Kang TB, Appel E, Kovalenko A, Wallach D. Caspase-8 deficiency facilitates cellular transformation in vitro. Cell Death Differ 2008;15:1350-5. [PMID: 18566604 DOI: 10.1038/cdd.2008.88] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
131 Lu H, Chou F, Yeh K, Chang Y, Hsu NC, Chang J. Analysing the expression of protein kinase C eta in human hepatocellular carcinoma. Pathology 2009;41:626-9. [DOI: 10.3109/00313020903273076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
132 Hirunwiwatkul P, Tirakunwichcha S, Meesuaypong P, Shuangshoti S. Orbital metastasis of hepatocellular carcinoma. J Neuroophthalmol 2008;28:47-50. [PMID: 18347459 DOI: 10.1097/WNO.0b013e31816754e7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
133 Fujiwara M, Marusawa H, Wang H, Iwai A, Ikeuchi K, Imai Y, Kataoka A, Nukina N, Takahashi R, Chiba T. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 2008;27:6002-11. [DOI: 10.1038/onc.2008.199] [Cited by in Crossref: 147] [Cited by in F6Publishing: 145] [Article Influence: 11.3] [Reference Citation Analysis]
134 Bengochea A, de Souza MM, Lefrançois L, Le Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer. 2008;99:143-150. [PMID: 18577996 DOI: 10.1038/sj.bjc.6604422] [Cited by in Crossref: 136] [Cited by in F6Publishing: 125] [Article Influence: 10.5] [Reference Citation Analysis]
135 van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer. 2011;47:1789-1797. [PMID: 21612914 DOI: 10.1016/j.ejca.2011.04.027] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
136 Fearon ER, Spence JR. Cancer biology: a new RING to Wnt signaling. Curr Biol 2012;22:R849-51. [PMID: 23058807 DOI: 10.1016/j.cub.2012.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
137 Kgatle MM, Setshedi M, Hairwadzi HN. Hepatoepigenetic Alterations in Viral and Nonviral-Induced Hepatocellular Carcinoma. Biomed Res Int. 2016;2016:3956485. [PMID: 28105421 DOI: 10.1155/2016/3956485] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
138 Berasain C, Castillo J, Prieto J, Avila MA. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 2007;27:174-85. [PMID: 17311611 DOI: 10.1111/j.1478-3231.2006.01424.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
139 Kent LN, Rakijas JB, Pandit SK, Westendorp B, Chen HZ, Huntington JT, Tang X, Bae S, Srivastava A, Senapati S, Koivisto C, Martin CK, Cuitino MC, Perez M, Clouse JM, Chokshi V, Shinde N, Kladney R, Sun D, Perez-Castro A, Matondo RB, Nantasanti S, Mokry M, Huang K, Machiraju R, Fernandez S, Rosol TJ, Coppola V, Pohar KS, Pipas JM, Schmidt CR, de Bruin A, Leone G. E2f8 mediates tumor suppression in postnatal liver development. J Clin Invest 2016;126:2955-69. [PMID: 27454291 DOI: 10.1172/JCI85506] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
140 Lu J, Hsia Y, Tu H, Hsiao Y, Yang W, Wang H, Yuh C. Liver development and cancer formation in zebrafish. Birth Defects Research Part C: Embryo Today: Reviews 2011;93:157-72. [DOI: 10.1002/bdrc.20205] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
141 Defamie V, Sanchez O, Murthy A, Khokha R. TIMP3 controls cell fate to confer hepatocellular carcinoma resistance. Oncogene. 2015;34:4098-4108. [PMID: 25347747 DOI: 10.1038/onc.2014.339] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
142 Zhang Z, Ma F, Zhou F, Chen Y, Wang X, Zhang H, Zhu Y, Bi J, Zhang Y. Functional polymorphisms of circadian negative feedback regulation genes are associated with clinical outcome in hepatocellular carcinoma patients receiving radical resection. Med Oncol 2014;31:179. [PMID: 25344870 DOI: 10.1007/s12032-014-0179-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
143 Yang SF, Chang CW, Wei RJ, Shiue YL, Wang SN, Yeh YT. Involvement of DNA damage response pathways in hepatocellular carcinoma. Biomed Res Int 2014;2014:153867. [PMID: 24877058 DOI: 10.1155/2014/153867] [Cited by in Crossref: 21] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
144 Bioulac-sage P, Balabaud C, Zucman-rossi J. Apport de l’immunohistochimie dans le diagnostic des tumeurs hépatocellulaires bénignes. Annales de Pathologie 2010;30:439-47. [DOI: 10.1016/j.annpat.2010.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
145 Qu JH, Chang XJ, Lu YY, Bai WL, Chen Y, Zhou L, Zeng Z, Wang CP, An LJ, Hao LY, Xu GL, Gao XD, Lou M, Lv JY, Yang YP. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2012;18:2995-3003. [PMID: 22736924 DOI: 10.3748/wjg.v18.i23.2995] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
146 Peyrou M, Bourgoin L, Foti M. PTEN in liver diseases and cancer. World J Gastroenterol. 2010;16:4627-4633. [PMID: 20872961 DOI: 10.3748/wjg.v16.i37.4627] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
147 Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, Galun E. The H19 non-coding RNA is essential for human tumor growth. PLoS One. 2007;2:e845. [PMID: 17786216 DOI: 10.1371/journal.pone.0000845] [Cited by in Crossref: 482] [Cited by in F6Publishing: 459] [Article Influence: 34.4] [Reference Citation Analysis]
148 Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007;75:770-87. [DOI: 10.1111/j.1432-0436.2007.00238.x] [Cited by in Crossref: 209] [Cited by in F6Publishing: 199] [Article Influence: 14.9] [Reference Citation Analysis]
149 Hamamoto H, Maemura K, Matsuo K, Taniguchi K, Tanaka Y, Futaki S, Takeshita A, Asai A, Hayashi M, Hirose Y, Kondo Y, Uchiyama K. Delta-like 3 is silenced by HBx via histone acetylation in HBV-associated HCCs. Sci Rep 2018;8:4842. [PMID: 29555949 DOI: 10.1038/s41598-018-23318-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
150 Gao Q, Shi Y, Wang X, Zhou J, Qiu S, Fan J. Translational medicine in hepatocellular carcinoma. Front Med. 2012;6:122-133. [PMID: 22573220 DOI: 10.1007/s11684-012-0193-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
151 Roner MR, Carraher CE Jr, Dhanji S, Barot G. Antiviral and Anticancer Activity of Cisplatin Derivatives of Tilorone. J Inorg Organomet Polym Mater 2008;18:374. [PMID: 32214933 DOI: 10.1007/s10904-008-9219-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
152 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 10.5] [Reference Citation Analysis]
153 Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol. 2010;15:242-255. [PMID: 20509038 DOI: 10.1007/s10147-010-0089-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
154 Alison MR, Lin WR. Regenerating the liver: not so simple after all? F1000Res 2016;5:F1000 Faculty Rev-1818. [PMID: 27508069 DOI: 10.12688/f1000research.8827.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
155 Archbold HC, Yang YX, Chen L, Cadigan KM. How do they do Wnt they do?: regulation of transcription by the Wnt/β-catenin pathway. Acta Physiol (Oxf) 2012;204:74-109. [PMID: 21624092 DOI: 10.1111/j.1748-1716.2011.02293.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 8.8] [Reference Citation Analysis]
156 Kavak E, Najafov A, Ozturk N, Seker T, Cavusoglu K, Aslan T, Duru AD, Saygili T, Hoxhaj G, Hiz MC, Unal DO, Birgül-iyison N, Ozturk M, Koman A. Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets. Cellular Signalling 2010;22:1523-35. [DOI: 10.1016/j.cellsig.2010.05.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
157 Shi B, Abrams M, Sepp-Lorenzino L. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J Histochem Cytochem. 2013;61:901-909. [PMID: 23979840 DOI: 10.1369/0022155413503662] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
158 Medhi S, Sarma MP, Asim M, Kar P. Genetic variants of heat shock protein A1L2437 and A1B1267 as possible risk factors for hepatocellular carcinoma in India. J Viral Hepat 2013;20:e141-7. [PMID: 23490384 DOI: 10.1111/jvh.12021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
159 Gao H, Yin FF, Guan DX, Feng YX, Zheng QW, Wang X, Zhu M, Zhang XL, Cheng SQ, Chen TW, Jiang H, Zhang EB, Wang JJ, Ni QZ, Yuan YM, Zhang FK, Ma N, Cao HJ, Wang YK, Li JJ, Xie D. Liver cancer: WISP3 suppresses hepatocellular carcinoma progression by negative regulation of β-catenin/TCF/LEF signalling. Cell Prolif 2019;52:e12583. [PMID: 30793395 DOI: 10.1111/cpr.12583] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
160 Li P, Ramm GA, Macdonald GA. Value of the 8-oxodG/dG ratio in chronic liver inflammation of patients with hepatocellular carcinoma. Redox Biol 2016;8:259-70. [PMID: 26890046 DOI: 10.1016/j.redox.2016.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
161 Wang W, Smits R, Hao H, He C. Wnt/β-Catenin Signaling in Liver Cancers. Cancers (Basel) 2019;11:E926. [PMID: 31269694 DOI: 10.3390/cancers11070926] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
162 McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto G, Cervello M, Libra M, Nicoletti F, Scalisi A, Torino F, Fenga C, Neri LM, Marmiroli S, Cocco L, Martelli AM. Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. Biochim Biophys Acta 2016;1863:2942-76. [PMID: 27612668 DOI: 10.1016/j.bbamcr.2016.09.004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 17.0] [Reference Citation Analysis]
163 Tennis M, Van Scoyk M, Winn RA. Role of the wnt signaling pathway and lung cancer. J Thorac Oncol. 2007;2:889-892. [PMID: 17909349 DOI: 10.1097/JTO.0b013e318153fdb1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
164 Zucman-rossi J. Human and mouse hepatocellular adenoma and carcinoma display similar tumorigenesis pathway alterations. Journal of Hepatology 2008;48:884-6. [DOI: 10.1016/j.jhep.2008.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
165 Reed CA, Mayhew CN, McClendon AK, Yang X, Witkiewicz A, Knudsen ES. RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1. Oncogene 2009;28:4434-43. [PMID: 19838213 DOI: 10.1038/onc.2009.303] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
166 Anuja K, Roy S, Ghosh C, Gupta P, Bhattacharjee S, Banerjee B. Prolonged inflammatory microenvironment is crucial for pro-neoplastic growth and genome instability: a detailed review. Inflamm Res 2017;66:119-28. [PMID: 27653961 DOI: 10.1007/s00011-016-0985-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
167 Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC, Lin SF, Su WW, Chang JG. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog. 2008;925-933. [PMID: 18444243 DOI: 10.1002/mc.20446] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 7.5] [Reference Citation Analysis]
168 Farra R, Dapas B, Pozzato G, Scaggiante B, Agostini F, Zennaro C, Grassi M, Rosso N, Giansante C, Fiotti N. Effects of E2F1-cyclin E1-E2 circuit down regulation in hepatocellular carcinoma cells. Dig Liver Dis. 2011;43:1006-1014. [PMID: 21831731 DOI: 10.1016/j.dld.2011.07.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
169 Bolondi L, Gramantieri L. From liver cirrhosis to HCC. Intern Emerg Med 2011;6 Suppl 1:93-8. [PMID: 22009618 DOI: 10.1007/s11739-011-0682-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
170 Wang B, Zhao L, Fish M, Logan CY, Nusse R. Self-renewing diploid Axin2(+) cells fuel homeostatic renewal of the liver. Nature. 2015;524:180-185. [PMID: 26245375 DOI: 10.1038/nature14863] [Cited by in Crossref: 420] [Cited by in F6Publishing: 351] [Article Influence: 70.0] [Reference Citation Analysis]
171 Tripathi LP, Kambara H, Moriishi K, Morita E, Abe T, Mori Y, Chen YA, Matsuura Y, Mizuguchi K. Proteomic analysis of hepatitis C virus (HCV) core protein transfection and host regulator PA28γ knockout in HCV pathogenesis: a network-based study. J Proteome Res. 2012;11:3664-3679. [PMID: 22646850 DOI: 10.1021/pr300121a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
172 Chen H, Wong CC, Liu D, Go MYY, Wu B, Peng S, Kuang M, Wong N, Yu J. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target. Theranostics 2019;9:5246-60. [PMID: 31410213 DOI: 10.7150/thno.34713] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
173 Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V, Dimitriadis G. Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;12:1347-57. [DOI: 10.1586/era.12.113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
174 Zubaidah RM, Tan GS, Tan SBE, Lim SG, Lin Q, Chung MCM. 2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics 2008;8:5086-96. [DOI: 10.1002/pmic.200800322] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
175 Aleksic K, Lackner C, Geigl JB, Schwarz M, Auer M, Ulz P, Fischer M, Trajanoski Z, Otte M, Speicher MR. Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice. Hepatology 2011;53:895-904. [PMID: 21374661 DOI: 10.1002/hep.24133] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
176 Vilchez V, Turcios L, Marti F, Gedaly R. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol 2016;22:823-32. [PMID: 26811628 DOI: 10.3748/wjg.v22.i2.823] [Cited by in CrossRef: 131] [Cited by in F6Publishing: 115] [Article Influence: 32.8] [Reference Citation Analysis]
177 Han SI, Lim SC. Expression and Prognostic Significance of CDK8 and β-Catenin in Hepatocellular Carcinoma. In Vivo 2020;34:1387-94. [PMID: 32354935 DOI: 10.21873/invivo.11918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Sheahan S, Bellamy CO, Dunbar DR, Harrison DJ, Prost S. Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest. BMC Cancer 2007;7:215. [PMID: 18021445 DOI: 10.1186/1471-2407-7-215] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
179 Morisawa T, Marusawa H, Ueda Y, Iwai A, Okazaki IM, Honjo T, Chiba T. Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression. Int J Cancer. 2008;123:2735-2740. [PMID: 18781563 DOI: 10.1002/ijc.23853] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
180 Serova M, Tijeras-Raballand A, Dos Santos C, Albuquerque M, Paradis V, Neuzillet C, Benhadji KA, Raymond E, Faivre S, de Gramont A. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget 2015;6:21614-27. [PMID: 26057634 DOI: 10.18632/oncotarget.4308] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 13.0] [Reference Citation Analysis]
181 Anestopoulos I, Voulgaridou GP, Georgakilas AG, Franco R, Pappa A, Panayiotidis MI. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacol Ther. 2015;145:103-119. [PMID: 25205159 DOI: 10.1016/j.pharmthera.2014.09.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
182 Kuo CY, Wang JC, Wu CC, Hsu SL, Hwang GY. Effects of hepatitis B virus X protein (HBx) on cell-growth inhibition in a CCL13-HBx stable cell line. Intervirology 2008;51:26-32. [PMID: 18309246 DOI: 10.1159/000118793] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
183 Audard V, Grimber G, Elie C, Radenen B, Audebourg A, Letourneur F, Soubrane O, Vacher-Lavenu MC, Perret C, Cavard C. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol. 2007;212:345-352. [PMID: 17487939 DOI: 10.1002/path.2169] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 6.7] [Reference Citation Analysis]
184 Dahmani R, Just PA, Perret C. The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35:709-713. [PMID: 21778132 DOI: 10.1016/j.clinre.2011.05.010] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
185 Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali KC. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer. 2009;8:90. [PMID: 19849855 DOI: 10.1186/1476-4598-8-90] [Cited by in Crossref: 124] [Cited by in F6Publishing: 113] [Article Influence: 10.3] [Reference Citation Analysis]
186 Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52:594-604. [PMID: 20185200 DOI: 10.1016/j.jhep.2009.10.033] [Cited by in Crossref: 259] [Cited by in F6Publishing: 250] [Article Influence: 23.5] [Reference Citation Analysis]
187 Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009;25:186-194. [PMID: 19387255 DOI: 10.1097/mog.0b013e32832962a1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 49] [Article Influence: 8.4] [Reference Citation Analysis]
188 Vinciguerra M, Carrozzino F, Peyrou M, Carlone S, Montesano R, Benelli R, Foti M. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. J Hepatol. 2009;50:1132-1141. [PMID: 19398230 DOI: 10.1016/j.jhep.2009.01.027] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
189 Hua Y, Yang Y, Li Q, He X, Zhu W, Wang J, Gan X. Oligomerization of Frizzled and LRP5/6 protein initiates intracellular signaling for the canonical WNT/β-catenin pathway. J Biol Chem 2018;293:19710-24. [PMID: 30361437 DOI: 10.1074/jbc.RA118.004434] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
190 Liu H, Ye Z, Kim Y, Sharkis S, Jang YY. Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology. 2010;51:1810-1819. [PMID: 20432258 DOI: 10.1002/hep.23626] [Cited by in Crossref: 178] [Cited by in F6Publishing: 158] [Article Influence: 16.2] [Reference Citation Analysis]
191 Zhang N, Wang L, Chai ZT, Zhu ZM, Zhu XD, Ma DN, Zhang QB, Zhao YM, Wang M, Ao JY, Ren ZG, Gao DM, Sun HC, Tang ZY. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling. PLoS One 2014;9:e115949. [PMID: 25542041 DOI: 10.1371/journal.pone.0115949] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
192 Toiyama Y, Inoue Y, Yasuda H, Yoshiyama S, Araki T, Miki C, Kusunoki M. Hepatocellular adenoma containing hepatocellular carcinoma in a male patient with familial adenomatous polyposis coli: Report of a case. Surg Today 2011;41:1442-6. [PMID: 21922375 DOI: 10.1007/s00595-010-4451-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
193 Wu Y, He Y, Zhang H, Dai X, Zhou X, Gu J, Wang G, Zhu J. A stringent dual control system overseeing transcription and activity of the Cre recombinase for the liver-specific conditional gene knock-out mouse model. Journal of Genetics and Genomics 2008;35:431-9. [DOI: 10.1016/s1673-8527(08)60060-0] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
194 Hua D, Hu Y, Wu YY, Cheng ZH, Yu J, Du X, Huang ZH. Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol. 2011;91:455-460. [PMID: 21600201 DOI: 10.1016/j.yexmp.2011.05.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
195 Chafey P, Finzi L, Boisgard R, Caüzac M, Clary G, Broussard C, Pégorier JP, Guillonneau F, Mayeux P, Camoin L. Proteomic analysis of beta-catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the Wnt pathway. Proteomics. 2009;9:3889-3900. [PMID: 19639598 DOI: 10.1002/pmic.200800609] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 4.9] [Reference Citation Analysis]
196 Ju H, Han K, Lee JD, Ro SW. Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy: Transgenic mouse models generated by hydrodynamic transfection. Int J Cancer 2016;138:1601-8. [DOI: 10.1002/ijc.29703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
197 Moghe A, Monga SP. BCL9/BCL9L in hepatocellular carcinoma: will it or Wnt it be the next therapeutic target? Hepatol Int 2020;14:460-2. [PMID: 32488834 DOI: 10.1007/s12072-020-10059-5] [Reference Citation Analysis]
198 Buendia MA. Tumor suppressors in hepatocellular carcinoma: many are called, but few are chosen. J Hepatol 2007;46:546-8. [PMID: 17313992 DOI: 10.1016/j.jhep.2007.01.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
199 Katoh H, Ojima H, Kokubu A, Saito S, Kondo T, Kosuge T, Hosoda F, Imoto I, Inazawa J, Hirohashi S. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology. 2007;133:1475-1486. [PMID: 17983802 DOI: 10.1053/j.gastro.2007.08.038] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
200 Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S235-41. [PMID: 20547309 DOI: 10.1016/S1590-8658(10)60511-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
201 Pei Y, Zhang T, Renault V, Zhang X. An overview of hepatocellular carcinoma study by omics-based methods. Acta Biochimica et Biophysica Sinica 2009;41:1-15. [DOI: 10.1093/abbs/gmn001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
202 Quélard D, Lavergne E, Hendaoui I, Elamaa H, Tiirola U, Heljasvaara R, Pihlajaniemi T, Clément B, Musso O. A cryptic frizzled module in cell surface collagen 18 inhibits Wnt/beta-catenin signaling. PLoS One. 2008;3:e1878. [PMID: 18382662 DOI: 10.1371/journal.pone.0001878] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
203 Xu CS, Zhang SB, Chen XG, Rahman S. Correlation analysis of liver tumor-associated genes with liver regeneration. World J Gastroenterol 2007;13:3323-32. [PMID: 17659671 DOI: 10.3748/wjg.v13.i24.3323] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
204 Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009;15:5895-901. [PMID: 19737952 DOI: 10.1158/1078-0432.CCR-09-0465] [Cited by in Crossref: 73] [Cited by in F6Publishing: 32] [Article Influence: 6.1] [Reference Citation Analysis]
205 Alison MR, Lin WR. Diverse routes to liver regeneration. J Pathol. 2016;238:371-374. [PMID: 26510495 DOI: 10.1002/path.4667] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
206 Huynh TT, Rao YK, Lee WH, Chen HA, Le TD, Tzeng DT, Wang LS, Wu AT, Lin YF, Tzeng YM, Yeh CT. Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition. Toxicol In Vitro 2014;28:552-61. [PMID: 24434019 DOI: 10.1016/j.tiv.2014.01.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
207 Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: Implications for imaging and management. Radiology. 2011;258:673-693. [PMID: 21339346 DOI: 10.1148/radiol.10100376] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
208 Mendy M, Walton R. Molecular pathogenesis and early detection of hepatocellular carcinoma--perspectives from West Africa. Cancer Lett. 2009;286:44-51. [PMID: 19523756 DOI: 10.1016/j.canlet.2009.04.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
209 Giakoustidis A, Giakoustidis D, Mudan S, Sklavos A, Williams R. Molecular signalling in hepatocellular carcinoma: Role of and crosstalk among WNT/ß-catenin, Sonic Hedgehog, Notch and Dickkopf-1. Can J Gastroenterol Hepatol 2015;29:209-17. [PMID: 25965442 DOI: 10.1155/2015/172356] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
210 Zhang G, Wang Q, Xu R. Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr Genomics 2010;11:311-25. [PMID: 21286309 DOI: 10.2174/138920210791616671] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
211 Hagymási K, Tulassay Z. Epidemiology, risk factors and molecular pathogenesis of primary liver cancer. Orvosi Hetilap 2008;149:541-8. [DOI: 10.1556/oh.2008.28313] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
212 Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 2007;252:157-170. [PMID: 17188425 DOI: 10.1016/j.canlet.2006.11.010] [Cited by in Crossref: 156] [Cited by in F6Publishing: 146] [Article Influence: 10.4] [Reference Citation Analysis]
213 Lu H, Chou F, Yeh K, Chang Y, Hsu NC, Chang J. Expression of Protein Kinase C Family in Human Hepatocellular Carcinoma. Pathol Oncol Res 2010;16:385-91. [DOI: 10.1007/s12253-009-9228-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
214 Ma BB, Sung F, Tao Q, Poon FF, Lui VW, Yeo W, Chan SL, Chan AT. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs. 2010;28:107-114. [PMID: 19172229 DOI: 10.1007/s10637-009-9219-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
215 Cai YR, Gong L, Teng XY, Zhang HT, Wang CF, Wei GL, Guo L, Ding F, Liu ZH, Pan QJ. Clonality and allelotype analyses of focal nodular hyperplasia compared with hepatocellular adenoma and carcinoma. World J Gastroenterol. 2009;15:4695-4708. [PMID: 19787833 DOI: 10.3748/wjg.15.4695] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
216 Xu J, Zhou J, Li MS, Ng CF, Ng YK, Lai PB, Tsui SK. Transcriptional regulation of the tumor suppressor FHL2 by p53 in human kidney and liver cells. PLoS One 2014;9:e99359. [PMID: 25121502 DOI: 10.1371/journal.pone.0099359] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
217 Su H, Zhao J, Xiong Y, Xu T, Zhou F, Yuan Y, Zhang Y, Zhuang SM. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutat Res. 2008;641:27-35. [PMID: 18358501 DOI: 10.1016/j.mrfmmm.2008.02.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
218 Chen J, Chen S, Wang J, Zhang M, Gong Z, Wei Y, Li L, Zhang Y, Zhao X, Jiang S, Yu L. Cyclophilin J is a novel peptidyl-prolyl isomerase and target for repressing the growth of hepatocellular carcinoma. PLoS One 2015;10:e0127668. [PMID: 26020957 DOI: 10.1371/journal.pone.0127668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
219 Anwar SL, Krech T, Hasemeier B, Schipper E, Schweitzer N, Vogel A, Kreipe H, Lehmann U. Deregulation of RB1 expression by loss of imprinting in human hepatocellular carcinoma. J Pathol 2014;233:392-401. [PMID: 24838394 DOI: 10.1002/path.4376] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
220 Carreira-Barbosa F, Nunes SC. Wnt Signaling: Paths for Cancer Progression. Adv Exp Med Biol. 2020;1219:189-202. [PMID: 32130700 DOI: 10.1007/978-3-030-34025-4_10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]